Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Indivior Pharmaceuticals (INDV) Cost of Revenue (2024 - 2025)

Indivior Pharmaceuticals (INDV) has 2 years of Cost of Revenue data on record, last reported at $67.0 million in Q4 2025.

  • For Q4 2025, Cost of Revenue rose 39.58% year-over-year to $67.0 million; the TTM value through Dec 2025 reached $246.0 million, up 6.49%, while the annual FY2025 figure was $246.0 million, 6.49% up from the prior year.
  • Cost of Revenue reached $67.0 million in Q4 2025 per INDV's latest filing, down from $83.0 million in the prior quarter.
  • Across five years, Cost of Revenue topped out at $83.0 million in Q3 2025 and bottomed at $38.0 million in Q1 2024.